Our team

The Renal Lifecycle study is coordinated from the University Medical Center Groningen (Sponsor) and was set up with the help of a grant through the Kidney Foundation. We collaborate with a large group of experts on various committees.

Research team University Medical Center Groningen

  • Prof. dr. R.T. Gansevoort, principal investigator (PI)
  • Prof. Dr. H.J. Lambers Heerspink, co-principal investigator (co-PI)
  • Prof. Dr. S. Berger, co-principal investigator (co-PI)
  • Y. Adema, research nurse
  • H.H. Nijmeijer, trial coordinator
  • Drs. W.M. Bakker, trial physician

Trial Steering Committee

The steering committee is responsible for the overall supervision of the study and provides scientific advice on all aspects of study design, protocol development, implementation and data collection. The steering committee is the decision-making body responsible for implementing changes to the protocol, including potential changes that may result from recommendations of the study’s Data Safety Monitoring Committee/Safety Committee.

The steering committee is advised by an International Scientific Advisory Committee and by members of the Patient Advisory Committee. Members of the steering committee are: dr. J. van der Net, prof. dr. M. Vervloet, dr. A. de Vries, prof. dr. M. Hemmelder, dr. R van Kruijsdijk, dr. A. Abrahams, prof. dr. D. Kuyper, prof. dr. S. Badve, A/prof. dr. C. Arnott, dr. L. Jakulj, prof. dr. C. Wanner and the UMCG team.

Security Committee

The safety committee is the data and safety advisory committee of the study. The safety committee monitors the interests of the participants, assessing the safety and efficacy of the intervention during the study and monitoring the overall conduct of the study. In doing so, this committee provides advice to the TSC. Members of the safety committee are Prof. Dr. A. Hoitsma, Dr. W. van Dorp, Dr. K. Halma and Dr. N. Veeger.

Endpoints Committee

The endpoints committee is responsible for reviewing suspected clinical endpoints for hospitalization due to heart failure and death due to renal failure. And possibly for other primary or secondary endpoints that lead to discussion within the steering committee. The CAC should determine whether the local investigators’ assessment of the endpoint is accurate and complete. If not, the CAC will judge the investigators’ assessment. The investigators will have to accept the CAC’s assessment. Members of the CAC are Prof. Dr. M. Walsh, Prof. Dr. P van der Meer and Prof. Dr. C. Gaillard.